Q2 2026 Krystal Biotech Inc Earnings Call Transcript
Key Points
- Krystal Biotech Inc (KRYS) reported strong US commercial performance with $91.6 million in net revenue for Q2 2026, contributing to a 24% year-over-year increase in total global sales.
- The company surpassed its initial US patient penetration target of 60%, achieving more than 730 reimbursement approvals for VYJUVEK, indicating sustained demand and market expansion.
- Krystal Biotech Inc (KRYS) maintains a robust financial position with over $1.1 billion in cash and investments, enabling continued investment in global expansion and pipeline development.
- The clinical pipeline is advancing with two registrational studies underway (KB803 for ocular lesions in DEB and KB801 for neurotrophic keratitis), with KB803 fully enrolled and on track for a readout later this year.
- The oncology program, inhaled KB707 for NSCLC, showed promising results with a 31% objective response rate in combination with pembrolizumab, and is on track for a registrational study in 2027.
- International expansion is progressing with marketing authorization granted in the UK and multiple regulatory submissions planned in Switzerland and Australia, alongside ongoing pricing and reimbursement discussions in key EU markets.
- European and Japanese revenue was broadly flat in Q2 2026 due to a reserve provision related to ongoing pricing negotiations in Germany, creating a near-term financial headwind.
- The pricing and reimbursement process in Germany is expected to continue into Q3 2026, with the company accruing revenue conservatively, which may continue to impact reported net revenue.
- In France, formal pricing and reimbursement discussions are not expected to progress until 2027, delaying potential revenue recognition and market access in that country.
- The NK registrational study (KB801) enrollment completion has been pushed to year-end 2026, with data readout expected in early 2027, slightly later than previously anticipated.
- The ocular DEB study (KB803) is US-only due to challenges with patient-reported outcomes acceptance in Europe, potentially limiting the initial global market opportunity for this indication.
- International launch dynamics, including fragmented care landscapes in Germany and intensive prescription renewal requirements in Japan, pose operational challenges that could affect treatment continuity and patient compliance.
Thank you for standing by, and welcome to the Krystal Biotech 2Q 2026 conference call. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to hand the conference over to your host, Stephane Paquette, Senior Vice President of Corporate Development. Please begin.
Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the second quarter of 2026. The press release is available on our website at www.Krystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today.
Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development, Executive Vice President and General Manager for Europe, Christine Wilson, Senior Vice President and Head of US.
Commercial; and Kate Romano, Chief Account Officer.
This
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
